WEEKLY EPIDEMIOLOGY BULLETIN

NATIONAL SURVEILLANCE UNIT, MINISTRY OF HEALTH & WELLNESS, JAMAICA

Weekly Spotlight

Brain Health



Brain health is the state of brain functioning across cognitive, sensory, social-emotional, behavioural and motor domains, allowing a person to realize their full potential over the life course, irrespective of the presence or absence of disorders. Different determinants related to physical health, healthy

environments, safety and security, life-long learning and social connection as well as access to quality services influence the way our brains develop, adapt and respond to stress and adversity. These give way to strategies for promotion and prevention across the life course. Optimizing brain health by addressing these determinants not only improves mental and physical health but also creates positive social and economic impacts that contribute to greater well-being and help advance society.

However, conditions affecting the brain and nervous system in general emerge throughout the life course and are characterized by disruptions in brain growth, damage to brain structure and/or impaired brain functioning. These include for example congenital and neurodevelopmental conditions as well as neurological disorders across the life. Health and social care for these conditions require multisectoral and interdisciplinary collaborations with a holistic person-centred approach focused on promotion, prevention, treatment, care and rehabilitation and the active engagement of persons with lived experience, their families and carers.

The global burden of neurological and neurodevelopmental conditions is high, with approximately 70% of the burden in low- and middle-income countries. Neurological conditions are the leading cause of disability adjusted life years (DALYs) and account for about 9 million deaths per year. The largest contributors of neurological DALYs in 2016 were stroke (42.2%), migraine (16.3%), dementia (10.4%), meningitis (7.9%) and epilepsy (5%). Parkinson disease, propelled by an increasingly ageing population, is the fastest growing neurological disorder. Premature birth, neonatal encephalopathy and neuroinfections contribute substantially to high disease burden in South-East Asia and Africa. In 2016, developmental disabilities accounted for 13.3% of the 29.3 million years lived with disability for all health conditions among children younger than 5 years.

Despite the large burden, only 28% of low-income countries have a dedicated policy for neurological diseases in comparison with 64% of high-income countries. Available resources for these conditions are insufficient in most countries, with unacceptably high treatment gaps for many neurological and neurodevelopmental conditions. For example, in low- and middle-income countries, there are only three adult neurologists per 10 million people while high-income countries have approximately 160 times more. Resources for the assessment and care of children with neurological and neurodevelopmental conditions are even more scarce.

Taken from WHO website on 18/September/2024 https://www.who.int/health-topics/brain-health#tab=tab_1 https://www.who.int/health-topics/brain-health#tab=tab_2

EPI WEEK 36



Syndromic Surveillance

Accidents


Violence

Pages 2-4



Class 1 Notifiable Events

Page 5



COVID-19

Page 6



Influenza

Page 7



Dengue Fever

Page 8




Research Paper

Page 9

SENTINEL SYNDROMIC SURVEILLANCE

Sentinel Surveillance in **Jamaica**





Sentinel surveillance occurs when selected health facilities (sentinel sites) form a network that reports on certain health conditions on a regular basis, for example, weekly. Reporting is mandatory whether or not there are cases to report.

Jamaica's sentinel surveillance system concentrates on visits to sentinel sites for health events and syndromes of national importance which are reported weekly (see pages 2 -4). There are seventy-eight (78) reporting sentinel sites (hospitals and health centres) across Jamaica.

Table showcasing the **Timeliness of Weekly Sentinel Surveillance** Parish Reports for the Four **Most Recent Epidemiological Weeks -**33 to 36 of 2024

Parish health departments submit reports weekly by 3 p.m. on Tuesdays. Reports submitted after 3 p.m. are considered late.

KEY:

Yellow- late submission on **Tuesday**

Red - late submission after **Tuesday**


Epi week	Kingston and Saint Andrew	Saint Thomas	Saint Catherine	Portland	Saint Mary	Saint Ann	Trelawny	Saint James	Hanover	Westmoreland	Saint Elizabeth	Manchester	Clarendon
2024													
33	On	On	On	On	On	On	On	On	On	On	On	On	On
	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time
34	On	On	On	On	On	On	On	On	Late	On	On	On	On
	Time	Time	Time	Time	Time	Time	Time	Time	(T)	Time	Time	Time	Time
35	On	On	On	On	On	On	On	On	On	On	On	On	On
	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time
36	On	late	On	On	On	On	On	On	On	On	On	On	On
	Time	(w)	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time

REPORTS FOR SYNDROMIC SURVEILLANCE

UNDIFFERENTIATED FEVER

Temperature of $>38^{\circ}C$ $/100.4^{\circ}F$ (or recent history of fever) with or without an obvious diagnosis or focus of infection.









INVESTIGATION **REPORTS-** Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued





FEVER AND NEUROLOGICAL

Temperature of >38°C /100.4°F (or recent history of fever) in a previously healthy person with or without headache and vomiting. The person must also have meningeal irritation, convulsions, altered consciousness, altered sensory manifestations or paralysis (except AFP).



FEVER AND HAEMORRHAGIC

Temperature of $>38^{\circ}C$ /100.40F (or recent history of fever) in a previously healthy person presenting with at least one haemorrhagic (bleeding) manifestation with or without jaundice.




FEVER AND JAUNDICE

Temperature of $>38^{\circ}C/100.4^{\circ}F$ (or recent history of fever) in a previously healthy person presenting with jaundice.


The epidemic threshold is used to confirm the emergence of an epidemic in order to implement control measures. It is calculated using the mean reported cases per week plus 2 standard deviations.




Weekly Visits to Sentinel Sites for Fever and Neurological Symptoms 2023 and 2024 vs. Weekly Threshold: Jamaica



Weekly visits to Sentinel Sites for Fever and Haemorrhagic 2023 and 2024 vs Weekly Threshold; Jamaica



Fever and Jaundice cases: Jamaica, Weekly Threshold vs Cases 2023 and 2024





NOTIFICATIONS-All clinical sites



INVESTIGATION **REPORTS-** Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued






ACCIDENTS

Any injury for which the cause is unintentional, e.g. motor vehicle, falls, burns, etc.





VIOLENCE

Any injury for which the cause is intentional, e.g. gunshot wounds, stab wounds, etc.




Weekly Visits to Sentinel Sites for Violence by Age Groups 2024 vs. Weekly **Threshold** 800 700 600 Number of Visits 500 400 300 200 100 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 Epidemiological Week Epi Threshold <5 y/o <5 y.o ■≥5 y.o - Epi Threshold ≥5y/o

GASTROENTERITIS

Inflammation of the stomach and intestines, typically resulting from bacterial toxins or viral infection and causing vomiting and diarrhoea.









INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued



CLASS ONE NOTIFIABLE EVENTS Comments Confirmed YTD^{α} AFP Field Guides from WHO indicate that for an **PREVIOUS CURRENT** CLASS 1 EVENTS effective surveillance YEAR 2024 **YEAR 2023** system, detection rates for 206^{β} 267^{β} **Accidental Poisoning** AFP should be 1/100,000 population under 15 years Cholera 0 0 NATIONAL /INTERNATIONAL old (6 to 7) cases annually. See Dengue page below Severe Dengue^y See Dengue page below COVID-19 (SARS-CoV-2) 637 3548 Pertussis-like syndrome and INTEREST Tetanus are clinically Hansen's Disease (Leprosy) 0 0 confirmed classifications. 50 16 Hepatitis B Hepatitis C 3 24 YDengue Hemorrhagic Fever data include Dengue HIV/AIDS NA NA related deaths: 2 3 Malaria (Imported) 9 21 δ Figures include all deaths Meningitis associated with pregnancy 0 Monkeypox 3 reported for the period. EXOTIC/ 0 0 Plague UNUSUAL ^εCHIKV IgM positive cases 0 0 Meningococcal Meningitis MORBIDITY, ^θ Zika PCR positive cases 0 0 Neonatal Tetanus β Updates made to prior Typhoid Fever 0 0 weeks. 1 2 Meningitis H/Flu ^α Figures are cumulative AFP/Polio totals for all epidemiological weeks year to date. Congenital Rubella Syndrome Congenital Syphilis SPECIAL PROGRAMMES Fever and Measles Rash Rubella Maternal Deaths^δ 43 Ophthalmia Neonatorum 94 102 Pertussis-like syndrome Rheumatic Fever Tetanus **Tuberculosis** 21 49 Yellow Fever Chikungunya² 0 0





Zika Virus⁰



INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued

0




SENTINEL REPORT- 78 sites. Automatic reporting

NA- Not Available

-19 Surveillance Update

		COAID
CASES	EW 36	Total
Confirmed	10	157374
Females	0	90682
Males	10	66689
Age Range	11 months to 84 years old	1 day to 108 years

- * 3 positive cases had no gender specification
- * PCR or Antigen tests are used to confirm cases
- * Total represents all cases confirmed from 10 Mar 2020 to the current Epi-Week.



- Contact of a Confirmed Case Imported
- Local Transmission (Not Epi Linked) Under Investigation
 - Workplace Cluster

■ Import Related


COVID-19 Outcomes

Outcomes	EW 36	Total		
ACTIVE		26		
2 weeks		20		
DIED – COVID	0	3862		
Related	U	3602		
Died - NON	0	382		
COVID	U	302		
Died - Under	0	151		
Investigation	U	151		
Recovered and	0	103226		
discharged	U	103220		
Repatriated	0	93		
Total		157374		

*Vaccination programme March 2021 - YTD

* Total as at current Epi week


3298COVID-19 Related Deaths since March 1, 2021 - YTD Vaccination Status among COVID-19 Deaths




Fully Vaccinated

■ Partially Vaccinated Unvacccinated

COVID-19 Parish Distribution and Global Statistics



COVID-19 WHO Global Statistics EW 33-36, 2024					
Epi Week	Confirmed Cases	Deaths			
33	62900	1300			
34	61100	1200			
35	62500	1100			
36	63400	890			
Total (4weeks)	249900	4490			



NOTIFICATIONS-All clinical sites



INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued






NATIONAL SURVEILLANCE UNIT INFLUENZA REPORT

EW 36


September 1, 2024 – September 7, 2024 Epidemiological Week 36

	EW 36	YTD
SARI cases	9	226
Total Influenza positive Samples	0	135
Influenza A	0	130
H3N2	0	36
H1N1pdm09	0	94
Not subtyped	0	0
Influenza B	0	5
B lineage not determined	0	0
B Victoria	0	5
Parainfluenza	0	0
Adenovirus	0	0
RSV	0	37



Epi Week Summary

During EW 36, nine (9) SARI admissions were reported.




Caribbean Update EW 36

Caribbean: ILI cases have maintained a declining trend associated with a higher proportion of positive influenza cases. SARI cases have remained low, with the majority of positive cases attributed to SARS-CoV-2. Influenza activity has been declining over the past four EW, with A(H3N2) being predominant, following by A(H1N1)pdm09. RSV activity has remained low and SARS-CoV-2 activity remains high, though declining.

By country: In the last four EW, influenza activity has been observed in Belize, the Dominican Republic, Saint Lucia, Suriname and Guyana. Additionlly, SARS-CoV-2 activity has been recorded in Belize, Haiti, Jamaica, Saint Lucia Barbados, Guyana, and Saint Vincent and the Grenadines. RSV activity has been detected in the Dominican Republic and Guyana.

(taken from PAHO Respiratory viruses weekly report) https://www.paho.org/en/influenza-situation-report



■ Adenovirus ■ B Victoria ■ RSV ■ B lineage non-determined ■ A not subtyped ■ Parainfluenza ■ SARS-CoV-2...■ A(H3N2) ■ A(H1N1)pdm09

7 NOTIFICATIONS-All clinical sites



INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued




Dengue Bulletin

September 1, 2024 – September 7, 2024 Epidemiological Week 36


Epidemiological Week 36





Reported suspected, probable and confirmed dengue with symptom onset in week 36 of 2024


	2024*			
	EW 36	YTD		
Total Suspected, Probable & Confirmed Dengue Cases	1	1666		
Lab Confirmed Dengue cases	0	40		
CONFIRMED Dengue Related Deaths	0	1		



Points to note:

- Dengue deaths are reported based on date of death.
- *Figure as at September 18, 2024
- Only PCR positive dengue cases are reported as confirmed.
- IgM positive cases are classified as presumed dengue.

Suspected, probable and confirmed dengue cases for 2022 - 2024 versus monthly mean, alert, and epidemic thresholds (2007-2022)



NOTIFICATIONS-All clinical sites



INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued





RESEARCH PAPER

Abstract

NHRC-23-016

The Impact of COVID-19 on Maternal Mortality in Jamaica

Gordon-Strachan G,¹ McCaw-Binns A²

¹Tropical Metabolism Research Unit, Caribbean Institute for Health Research, University of the West Indies, Mona, Kingston 7, Jamaica ²Adjunct Professor, Department of Community Health and Psychiatry, University of the West Indies, Mona, Kingston 7, Jamaica

Objective: To determine the impact of COVID-19 on maternal mortality by comparing the causes of and Maternal Mortality Ratio (MMR) per 100,000 live births for Jan-2020-Dec-2021 (COVID-19 period) and a pre-COVID-19 reference period (Jan-2018-Dec-2019).

Methods: Registered deaths for 1-Jan-2018 to 31-Dec-2021 in women 10-49 years with evidence of pregnancy were combined with MOHW-Maternal Mortality Surveillance data to create a master-list of maternal deaths. The master-list was cleaned and coded using WHO guidelines for maternal and COVID-19 deaths. Maternal deaths (pregnancy to 42 days post-partum) were disaggregated by year and period of occurrence, comparing the COVID-19 (2020-21) and pre-COVID-19 (2018-19) periods.

Results: The MMR increased from 136.8 in 2018/2019 to 172.2 during the COVID-19 period. The COVID-19 cause-specific MMR was 61.4 and was the leading cause of death during the period. Most COVID-19 deaths (39/41) occurred in 2021. The direct mortality ratio was unchanged at 86.8 for both periods, however obstetric haemorrhage replaced the hypertensive disorders of pregnancy as the leading direct cause of death in the latest period. The pregnancy mortality ratio for accidents and violence declined 54 percent between the two periods due to fewer violent deaths (8.8 versus 1.5/100,000). Mortality rates from accidents were unchanged (4.4).

Conclusion: The COVID-19 pandemic adversely affected the Jamaican MMR. The 2018-21 MMR of 154 represents an upward MMR trend from 92 (1998-03). Exclusion of COVID-19 deaths would reduce the 2018-21 ratio to 111, which was still above the 102 for 2010-15. Jamaica is unlikely to meet the SDG MMR goal of 70/100,000.



The Ministry of Health and Wellness

15 Knutsford Boulevard, Kingston 5, Jamaica
Tele: (876) 633-7924
Email: surveillance@moh.gov.jm





INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued

